

PRESS RELEASE

January 06, 2026

Neurosom™ announces oversubscribed bridge round financing as company advances towards Seed Round in 1H 2026

Eugene, OR – Neurosom™, the developer of a personalized, at-home neuromodulation therapy to improve deep and REM sleep, key factors in reducing dementia risk, today announced the imminent closing of an oversubscribed bridge round of investment funding.

"We are incredibly grateful for this strong show of support for our Sleep WISP™ technology and the promise it provides for reducing dementia risk, optimizing sleep, and providing brain care as we age," said Viral Sheth, CEO of Neurosom.

The oversubscribed bridge round, led by Portland Seed Fund's Intrepid Oregon Fund with major participation from the Loomis Family Trust, OEN Angel Syndicate, and ONAMI reflects strong validation of Neurosom's technology and clinical trajectory.

"The Neurosom team directs decades of neuroscience and product expertise at some of the most pernicious health and longevity issues of our day," said Angela Jackson, managing director of Portland Seed Fund. We are thrilled to have led this investment round and look forward to its growth in the months and years to come."

In 2025, Neurosom™ achieved several key milestones, including the FDA clearance of NEAT™, its AI-powered software for the therapy system, and the phase II funding for a clinical trial for Mild Cognitive Impairment, or MCI, funded by the National Institute of Aging, helped drive a stellar year of recognition for Neurosom™ within the business and innovation communities.

On December 1st, Neurosom™ won the 2025 Oregon Entrepreneur Network (OEN) Angel Oregon Life & BioScience Fund Investment Award. Sheth commented, *"Neurosom is honored to win OEN's Angel Oregon BIO investment. This award serves as a powerful endorsement of our mission to transform deep sleep into a therapeutic gateway for brain health and dementia prevention. The mentorship and network we have been able to build throughout this program have been incredibly valuable. We are deeply grateful to OEN and the Oregon innovation community for their support as we bring Sleep WISP™ closer to the patients and families who need it most."*

Path to Seed Round and 2026 Outlook

In 2026, the funds raised during the bridge round will be strategically deployed to scale operations and support additional clinical trials targeting MCI.

Neurosom™ has entered active discussions with a select group of specialized neurotechnology investors to anchor a \$5 million priced seed financing targeted for the first half of 2026. The company will deepen these discussions with strategic neurotech investors during meetings around the **JP Morgan Healthcare Conference**.

“With multiple data milestones expected in 2026 and growing inbound interest from strategic neurotechnology venture firms, we anticipate the Seed Round to move quickly,” says Sheth.

On the Horizon

Key Opinion Leader Sites – the **Sleep WISP™** is now in use at **Mount Sinai, Oregon Health & Science University (OHSU), the University of Washington, Northwestern University, and Wake Forest University**. In 2026, the company will expand its clinical collaborations with additional key opinion leaders (KOLs) and private clinics to broaden its data foundation and accelerate real-world learning.

Product Development

Neurosom™ will continue advancing the **Sleep WISP™** platform, focusing on improved signal quality and comfort through refinements in hardware and electrodes to support long-term, at-home use with clinical-grade EEG and neuromodulation capability. In parallel, the company is developing an HD EEG based framework for memory and cognitive assessment, integrating longitudinal sleep EEG biomarkers, objective event-related potential (ERP) measures, and emerging biomarkers associated with glymphatic clearance capacity to support earlier detection of cognitive decline and personalized therapy optimization. Qualified investors and strategic partners are encouraged to contact **Neurosom™** through the website for additional information.

About Neurosom™

Neurosom™ is a medical device company dedicated to reducing dementia risk and improving brain health by optimizing deep and REM sleep. Founded in 2021, the company developed the innovative, wearable **Sleep WISP™** device, which measures EEG sleep cycles in the home and delivers personalized, painless electrical stimulation using AI-powered, FDA cleared software. By extending and enhancing deep and REM sleep – the sleep cycles that allow the body to clear the brain of the harmful plaques that cause neurodegenerative diseases.

Headquartered in Eugene, Oregon, **Neurosom™** is committed to advancing the future of sleep and brain health care. For more information, visit <https://neurosom.net>

